Bioinvent: Difference between revisions
Content deleted Content added
Yngvadottir (talk | contribs) Identified the refs. Bank listing was repeated. ''Dagens industri'' is a search - returning 3 articles, one or two of which may be useful. |
Dagens Nyheter |
||
| Line 3: | Line 3: | ||
<!-- Once discussion is closed, please place on talk page: {{Old AfD multi|page=Bioinvent|date=19 June 2019|result='''keep'''}} --> |
<!-- Once discussion is closed, please place on talk page: {{Old AfD multi|page=Bioinvent|date=19 June 2019|result='''keep'''}} --> |
||
<!-- End of AfD message, feel free to edit beyond this point --> |
<!-- End of AfD message, feel free to edit beyond this point --> |
||
'''BioInvent International''' is a Swedish research, pharmaceutical and life science company with focus on clinical development of antibody drugs for [[immunotherapy]] against [[cancer]]. The company was founded in 1983 by Carl Borrebaeck and is listed on the [[Stockholm Stock Exchange]] since 2001. The company's partners include [[Bayer HealthCare]], [[Daiichi Sankyo]], Mitsubishi Tanabe and [[Servier]]. Martin Welschof has been CEO since 2018.<ref>[https://news.cision.com/se/bioinvent/r/bioinvent-rekryterar-martin-welschof-som-ny-vd,c2493851 "BioInvent rekryterar Martin Welschof som ny vd"] (press release), Cision, 12 April 2018 (in Swedish).</ref><ref>[https://www.avanza.se/aktier/om-aktien.html/5505/bioinvent-international "BioInvent International"], Avanza Bank, retrieved 19 June 2019 (in Swedish).</ref><ref>[http://www.bioinvent.com/technology/ "Technology"], Bioinvent, retrieved 19 June 2019.</ref><ref>Kajsa-Stina Kalin, [https://www.sydsvenskan.se/2013-10-04/bioinvent-var-pionjarer-i-parken "Bioinvent var pionjärer i parken"] ''Sydsvenskan'', 4 October 2015 (in Swedish).</ref><ref>Maria Lindh, [http://www.lum.lu.se/forskningen-som-ledde-till-miljardavtalet/ "Forskningen som ledde till miljardavtalet"], ''LUM.'', Lund University, 11 September 2015 (in Swedish).</ref><ref>[https://www.di.se/amnen/bioinvent/ "Bioinvent"] (search result), ''Dagens industri'', retrieved 19 June 2019 (in Swedish).</ref> |
'''BioInvent International''' is a Swedish research, pharmaceutical and life science company with focus on clinical development of antibody drugs for [[immunotherapy]] against [[cancer]]. The company was founded in 1983 by Carl Borrebaeck and is listed on the [[Stockholm Stock Exchange]] since 2001. The company's partners include [[Bayer HealthCare]], [[Daiichi Sankyo]], Mitsubishi Tanabe and [[Servier]]. Martin Welschof has been CEO since 2018.<ref>[https://news.cision.com/se/bioinvent/r/bioinvent-rekryterar-martin-welschof-som-ny-vd,c2493851 "BioInvent rekryterar Martin Welschof som ny vd"] (press release), Cision, 12 April 2018 (in Swedish).</ref><ref>[https://www.avanza.se/aktier/om-aktien.html/5505/bioinvent-international "BioInvent International"], Avanza Bank, retrieved 19 June 2019 (in Swedish).</ref><ref>[http://www.bioinvent.com/technology/ "Technology"], Bioinvent, retrieved 19 June 2019.</ref><ref>Kajsa-Stina Kalin, [https://www.sydsvenskan.se/2013-10-04/bioinvent-var-pionjarer-i-parken "Bioinvent var pionjärer i parken"] ''Sydsvenskan'', 4 October 2015 (in Swedish).</ref><ref>Maria Lindh, [http://www.lum.lu.se/forskningen-som-ledde-till-miljardavtalet/ "Forskningen som ledde till miljardavtalet"], ''LUM.'', Lund University, 11 September 2015 (in Swedish).</ref><ref>[https://www.di.se/amnen/bioinvent/ "Bioinvent"] (search result), ''Dagens industri'', retrieved 19 June 2019 (in Swedish).</ref><ref>https://www.dn.se/ekonomi/bioinvent-i-nytt-cancersamarbete/</ref> |
||
== References == |
== References == |
||
Revision as of 07:57, 20 June 2019
An editor has nominated this article for deletion. You are welcome to participate in the deletion discussion, which will decide whether or not to retain it. |
BioInvent International is a Swedish research, pharmaceutical and life science company with focus on clinical development of antibody drugs for immunotherapy against cancer. The company was founded in 1983 by Carl Borrebaeck and is listed on the Stockholm Stock Exchange since 2001. The company's partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. Martin Welschof has been CEO since 2018.[1][2][3][4][5][6][7]
References
- ^ "BioInvent rekryterar Martin Welschof som ny vd" (press release), Cision, 12 April 2018 (in Swedish).
- ^ "BioInvent International", Avanza Bank, retrieved 19 June 2019 (in Swedish).
- ^ "Technology", Bioinvent, retrieved 19 June 2019.
- ^ Kajsa-Stina Kalin, "Bioinvent var pionjärer i parken" Sydsvenskan, 4 October 2015 (in Swedish).
- ^ Maria Lindh, "Forskningen som ledde till miljardavtalet", LUM., Lund University, 11 September 2015 (in Swedish).
- ^ "Bioinvent" (search result), Dagens industri, retrieved 19 June 2019 (in Swedish).
- ^ https://www.dn.se/ekonomi/bioinvent-i-nytt-cancersamarbete/